Pharma BD Deal Intelligence

AstraZeneca PLC / Amgen Inc.

2020 · Co-Development · $2.3B · Complete

Positive — critic reaction at announcement

Worked — the deal delivered on its rationale

CALLED IT — OFF BY 14

AstraZeneca and Amgen restructured their existing collaboration for tezepelumab (Tezspire), an anti-TSLP antibody for severe asthma. Under the updated terms, AstraZeneca made a $575M payment to Amgen to increase its share of tezepelumab economics (moving from 50/50 US split to AZ-favorable terms). Total consideration to Amgen across the original and restructured deals is approximately $2.3B including royalties. AZ gained global commercialization lead.

Key facts

Announced Sep 02, 2020
Closed Sep 02, 2020
Deal value $2.3B
Deal type Co-Development
Therapeutic area Respiratory
Indications Severe Asthma, Chronic Obstructive Pulmonary Disease (COPD), Chronic Rhinosinusitis with Nasal Polyps
Key assets tezepelumab (Tezspire)
Mechanism Anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody

Related deals — scored

Deal	Year	Value	Outcome
AstraZeneca PLC / Amgen Inc. (this deal)	2020	$2.3B	84
AstraZeneca PLC / Daiichi Sankyo Company, Limited	2019	$6.9B	100
AstraZeneca PLC / KuDOS Pharmaceuticals Limited	2005	$210M	98
AstraZeneca PLC / Alexion Pharmaceuticals Inc.	2020	$39.0B	86
AstraZeneca PLC / Acerta Pharma	2015	$4.0B	86
AstraZeneca PLC / MedImmune Inc.	2007	$15.6B	82
AstraZeneca PLC / CinCor Pharma Inc.	2023	$1.8B	78

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2020 deals · AstraZeneca PLC deals · Respiratory deals